Jardiance pharmacokinetics
Pro Research Analysisby 
Searched over 200M research papers for "Jardiance pharmacokinetics"
Jardiance (Empagliflozin) Pharmacokinetics: Absorption, Distribution, and Elimination
Empagliflozin, marketed as Jardiance, is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used primarily for type 2 diabetes management. After oral administration, empagliflozin is rapidly absorbed, with peak plasma concentrations (Cmax) typically reached within a few hours. Studies show that the time to reach maximum concentration (Tmax) can vary slightly depending on the timing of administration, with evening doses resulting in a 35% longer Tmax compared to morning doses, though this difference is not considered clinically significant. The maximum concentration (Cmax) and overall exposure (AUC) are similar between morning and evening dosing, indicating consistent absorption regardless of dosing time .
Bioequivalence and Formulation Comparisons
Multiple studies have demonstrated that generic formulations of empagliflozin are bioequivalent to the brand-name Jardiance. The key pharmacokinetic parameters—Cmax, AUC0-t, and AUC0-∞—fall within the accepted bioequivalence range (80–125%) for both fasting and fed conditions. This has been confirmed in healthy subjects across different populations, including Chinese and Korean volunteers, and with various formulations, such as cocrystal versions and standard tablets Li2020Peña2023Jiang2023+1 MORE. These findings mean that patients can expect similar drug exposure and effects from both generic and brand-name products.
Food Effects on Empagliflozin Pharmacokinetics
High-fat meals do not significantly affect the pharmacokinetics of empagliflozin. Studies show that Cmax, AUC, and Tmax remain consistent whether the drug is taken with or without food, supporting the recommendation that empagliflozin can be administered without regard to meals Li2020Chen2020.
Pharmacokinetic Consistency and Safety
Empagliflozin displays predictable pharmacokinetics with low potential for drug interactions and minimal side effects. The drug is well tolerated in healthy subjects, with no serious adverse events reported in pharmacokinetic studies. Its pharmacokinetic profile supports once-daily dosing, and the lack of significant differences between morning and evening administration or between fed and fasting states provides flexibility for patients ElDash2021Li2020Peña2023+2 MORE.
Mechanism of Action and Clinical Implications
Empagliflozin works by inhibiting SGLT2 in the kidneys, reducing glucose reabsorption and increasing urinary glucose excretion. This mechanism is reflected in pharmacodynamic studies, which show increased urinary glucose excretion after dosing, regardless of administration time ElDash2021Gamito2024Arun2022. The drug’s pharmacokinetic and pharmacodynamic properties contribute to its effectiveness in lowering blood glucose and providing cardiovascular and renal benefits in patients with type 2 diabetes Gamito2024Arun2022.
Conclusion
Jardiance (empagliflozin) demonstrates consistent and predictable pharmacokinetics across different formulations, dosing times, and food conditions. Generic and brand-name products are bioequivalent, and the drug is well tolerated with a low risk of interactions. These characteristics make empagliflozin a flexible and reliable option for managing type 2 diabetes.
Sources and full results
Most relevant research papers on this topic